4th Annual Neuropsychiatric Drug Development Summit | September 29-30, 2021 | Digital Event

Memo

This last year has been a brutal reminder as to how crucial it is that we tackle the impending global mental health crisis and find a path towards successful neuropsychiatric drug development. We are proud to be the industry’s definitive and unrivalled forum focused on encapsulating the recent clinical advances across this extremely arduous field. This timely meeting provides a much-needed platform for industry and academic thought leaders to: - Investigate new treatment paradigms to support schizophrenia patients with Sunovion, Merck, Cerevel and BioXcel - Strive for useful biomarkers in clinical practice and explore novel electrophysiological biomarkers of synaptic plasticity in humans with Lundbeck, Daniel Javitt and Takeda - Hear patient-centric approaches towards developing efficacious and engaging digital therapeutics with Thomas Insel, MindMed - Decipher the recent hype in psychedelics by evaluating new data emerging on hallucinogens with Psilera, MAPS, Eleusis, ATAI and Perception Neuroscience - Discover the major advances in understanding neuroinflammation across CNS indications and how can we use this to help us further understand psychiatric conditions with Johnson & Johnson and Inmune Bio Don’t miss out and join over 80 of your peers at this timely event to take a step closer towards your ambitious goal of drastically improving the lives of individuals living with neuropsychiatric disorders Prices:Conference + 1 Workshop - Drug Developer USD 2898.00Conference Only - Drug Developer USD 2399.00 Speakers: Heather Dworak Senior Director, Clinical Research Sunovion, Daniel Mathalon Professor of Psychiatry and Behavioral Sciences UCSF Weill Institute for Neurosciences, Stephen J. Ferrando Director of Psychiatry at Westchester Medical Center (WMC) Chairman of Psychiatry at New York Medical College, Amy Peters Instructor, Department of Psychiatry Massachusetts General Hospital & Harvard Medical School, Jonathan Rogers Wellcome Trust Clinical Training Fellow UCL Division of Psychiatry, Judith Ford Co-Director, Brain Imaging & EEG Lab, Professor, Department of Psychiatry, UCSF; Senior Research Career Scientist San Francisco Veterans Affairs Medical Center, Shlomi Raz Founder & CEO Eleusis, Michael De Vivo Vice President, Neuroscience BioXcel Therapeutics, John Renger Ph.D, Chief Scientific Officer Cerevel Therepeutics, Gary Zammit President & CEO Clinilabs, Srinivas Rao Co-Founder & Chief Scientific Officer Atai Life Sciences, Thomas Insel Co-founder Humanest Care, Chair Steinberg Institute, Robert Goldel Neuroscientist & Technologist, Jessica Malberg Director, Neuroscience Development INmune Bio, Anindya Bhattacharya Senior Director, Head Neuroimmunology, Neuroscience Therapeutic Area Janssen Pharmaceutical Companies of Johnson & Johnson, Isabella Premoli Imaging & Neurostimulation Specialist, Lundbeck, Pradeep Nathan Vice President & Head of Experimental Medicine & Professor of Neuroscience Lundbeck, Xiohai Wang Director, Neuroscience Merck, Daniel R Karlin CMO, MindMed, Rick Doblin Executive Director Multidisciplinary Association for Psychedelic Studies, Kurt Rasmussen Director, Division of Therapeutics & Medical Consequences National Institute on Drug Abuse, Daniel C. Javitt Director, Schizophrenia Research Program, Nathan S.Kline Institute for Psychiatric Research Professor & Director, Division of Experimental Therapeutics, Columbia University College, Terence A. Kelly CEO Perception Neuroscience, Jackie von Salm Co-Founder, CSO Psilera Bioscience, Patricio O’Donnell Executive Medical Director, Head of Neurocircuitry Modulation Biomarkers Takeda, Massimiliano Bianchi Founder / President & CEO Ulysses Neuroscience Date and Time: Starts Wed, Sep 29, 2021 at 8:30 AM and Ends Thu, Sep 30, 2021 at 6:00 PM